107 related articles for article (PubMed ID: 29986967)
1. Response by Ibrahim et al to Letter Regarding Article, "Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl)".
Ibrahim K; Shah R; McEvoy JW
Circulation; 2018 Jul; 138(2):216-217. PubMed ID: 29986967
[No Abstract] [Full Text] [Related]
2. Letter by Kikkert et al Regarding Article, "Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl)".
Kikkert WJ; Delewi R; Claessen BEPM
Circulation; 2018 Jul; 138(2):214-215. PubMed ID: 29986966
[No Abstract] [Full Text] [Related]
3. Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl).
McEvoy JW; Ibrahim K; Kickler TS; Clarke WA; Hasan RK; Czarny MJ; Keramati AR; Goli RR; Gratton TP; Brinker JA; Chacko M; Hwang CW; Johnston PV; Miller JM; Trost JC; Herzog WR; Blumenthal RS; Thiemann DR; Resar JR; Schulman SP
Circulation; 2018 Jan; 137(3):307-309. PubMed ID: 29046319
[No Abstract] [Full Text] [Related]
4. The Dose and Timing of Fentanyl Impacts on Ticagrelor Absorption and Platelet Inhibition During Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial.
Goli RR; Ibrahim K; Shah R; Kickler TS; Clarke WA; Resar JR; Schulman SP; McEvoy JW
J Invasive Cardiol; 2019 Sep; 31(9):265-271. PubMed ID: 31478892
[TBL] [Abstract][Full Text] [Related]
5. Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: Design, rationale, and sample characteristics of the PACIFY randomized trial.
Ibrahim K; Goli RR; Shah R; Resar JR; Schulman SP; McEvoy JW
Contemp Clin Trials; 2018 Jan; 64():8-12. PubMed ID: 29170073
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effect of Morphine and Fentanyl in patients with acute coronary syndrome receiving Ticagrelor - The COMET (Comparison Morphine, Fentayl and Ticagrelor) randomized controlled trial.
Senguttuvan NB; Suman F; Paneerselvam T; Malepati B; Ramesh S; Vallivedu MV; Badimela P; Ramadoss M; Iyer M; Krishnamurthy P; Vinod Kumar B; Balasubramaniyan JV; Sadhanandham S; Jebaraj R; Manokar P; Muralidharan TR; Murthy JS; Thanikachalam S; Krishnamoorthy P; Baber U; Karthikeyan G
Int J Cardiol; 2021 May; 330():1-6. PubMed ID: 33600846
[TBL] [Abstract][Full Text] [Related]
7. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
[TBL] [Abstract][Full Text] [Related]
9. Effect of Clopidogrel vs Ticagrelor on Platelet Aggregation and Inflammation Markers After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.
Jiang Z; Zhang R; Sun M; Liu Q; Wang S; Wang W; Zhao Q; Zhang H; Wang Y; Hou J; Yu B
Can J Cardiol; 2018 Dec; 34(12):1606-1612. PubMed ID: 30527148
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of P2Y12 receptor antagonists on platelet function and clinical outcomes in patients undergoing Primary PCI: A substudy of the HEAT-PPCI trial.
Shahzad A; Khanna V; Kemp I; Shaw M; Mars C; Cooper R; Wilson K; Curzen N; Stables RH
EuroIntervention; 2018 Mar; 13(16):1931-1938. PubMed ID: 29336311
[TBL] [Abstract][Full Text] [Related]
11. Antiplatelet Effect of Different Loading Doses of Ticagrelor in Patients With Non-ST-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: The APELOT Trial.
Liu HL; Wei YJ; Ding P; Zhang J; Li TC; Wang B; Wang MS; Li YT; Zhang JJ; Ren YH; Tang Q; Luo JP; Yang SL; Ma HY; Liu Y; Han W; Li Y; Jin ZG; Jin LM
Can J Cardiol; 2017 Dec; 33(12):1675-1682. PubMed ID: 29173606
[TBL] [Abstract][Full Text] [Related]
12. Effect of ticagrelor and clopidogrel on platelet aggregation function after percutaneous coronary intervention in patients with acute coronary syndrome.
Sui Z; Qu P
J Biol Regul Homeost Agents; 2019 Mar-Apr,; 33(2):439-445. PubMed ID: 30971068
[TBL] [Abstract][Full Text] [Related]
13. Effect of Chewing vs Swallowing Ticagrelor on Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial.
Asher E; Tal S; Mazin I; Abu-Much A; Sabbag A; Katz M; Regev E; Chernomordik F; Guetta V; Segev A; Elian D; Barbash I; Fefer P; Narodistky M; Beigel R; Matetzky S
JAMA Cardiol; 2017 Dec; 2(12):1380-1384. PubMed ID: 29071332
[TBL] [Abstract][Full Text] [Related]
14. Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.
Sweeny JM; Angiolillo DJ; Franchi F; Rollini F; Waksman R; Raveendran G; Dangas G; Khan ND; Carlson GF; Zhao Y; Teng R; Mehran R
J Am Heart Assoc; 2017 Mar; 6(4):. PubMed ID: 28356282
[TBL] [Abstract][Full Text] [Related]
15. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C
Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
Kim JS; Han DC; Jeong YH; Park DW; Sohn CB; Hwang KW; Lee SH; Choi JH; Chon MK; Lee SY; Hwang J; Kim IS; Lee SM; Han J; Noh M; Kim CH; Chun KJ; Park YH; Kim JH
Thromb Haemost; 2016 Jan; 115(1):213-21. PubMed ID: 26581884
[TBL] [Abstract][Full Text] [Related]
18. Randomized Comparison of Oral P2Y
Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the Antiplatelet Effects of Once and Twice Daily Low-Dose Ticagrelor and Clopidogrel After Percutaneous Coronary Intervention.
Choi KN; Jin HY; Shin HC; Park YA; Seo JS; Jang JS; Yang TH; Kim DK; Kim DS
Am J Cardiol; 2017 Jul; 120(2):201-206. PubMed ID: 28554486
[TBL] [Abstract][Full Text] [Related]
20. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
